Variability of the dietary-derived CYP2D6 activity marker solanidine in vivo

被引：0
|
作者：
Mueller, J. P. [1 ]
Saromba, J. [1 ]
Ziegler, P. [2 ]
Tremmef', R. [3 ,4 ]
Rengelshausen, J. [2 ]
Schaeffeler, E. [3 ,4 ]
Just, K. S. [1 ]
Schwab, M. [3 ,5 ,6 ]
Kraus, T. [2 ]
Sting, J. C. [1 ]
机构：
[1] Univ Hosp RWTH Aachen, Inst Clin Pharmacol, Aachen, Germany
[2] Univ Hosp RWTH Aachen, Inst Occupat Social & Environm Med, Aachen, Germany
[3] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[4] Univ Tubingen, Tubingen, Germany
[5] Univ Tubingen, Dept Clin Pharmacol, Tubingen, Germany
[6] Univ Tubingen, Dept Biochem & Pharm, Tubingen, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2024年 / 397卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P226
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [21] Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity
    Ducharme, J
    Abdullah, S
    Wainer, IW
    JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 678 (01): : 113 - 128
  • [22] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [23] The influence of clomipramine on CYP2D6 activity
    Szewczuk-Boguslawska, Monika
    Kiejna, Andrzej
    Grzesiak, Magdalena
    Beszlej, Jan Aleksander
    Chlebowska, Iwona
    Orzechowska-Juzwenko, Krystyna
    Milejski, Piotr
    PSYCHIATRIA POLSKA, 2007, 41 (02) : 243 - 249
  • [24] Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice
    Tolledo, Cole
    Stocco, Marlaina R.
    Miksys, Sharon
    Gonzalez, Frank J.
    Tyndale, Rachel F.
    MOLECULAR NEUROBIOLOGY, 2020, 57 (06) : 2509 - 2520
  • [25] Inhibition of CYP2D6 activity by bupropion
    Kotlyar, M
    Brauer, LH
    Tracy, TS
    Hatsukami, DK
    Harris, J
    Bronars, CA
    Adson, DE
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (03) : 226 - 229
  • [26] Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice
    Cole Tolledo
    Marlaina R. Stocco
    Sharon Miksys
    Frank J. Gonzalez
    Rachel F. Tyndale
    Molecular Neurobiology, 2020, 57 : 2509 - 2520
  • [27] Role of CYP2D6 in the demethylation of fluoxetine in vivo
    Hamelin, BA
    Turgeon, J
    Vallee, F
    Belanger, PM
    Paquet, F
    LeBel, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI33 - PI33
  • [28] Investigation of terbinafine as a CYP2D6 inhibitor in vivo
    Abdel-Rahman, SM
    Gotschall, RR
    Kauffman, RE
    Leeder, JS
    Kearns, GL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (05) : 465 - 472
  • [29] Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo
    Ozdemir, V
    Naranjo, CA
    Shulman, RW
    Herrmann, N
    Sellers, EM
    Reed, K
    Kalow, W
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (03) : 198 - 207
  • [30] The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6
    Fukuda, T
    Nishida, Y
    Imaoka, S
    Hiroi, T
    Naohara, M
    Funae, Y
    Azuma, J
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2000, 380 (02) : 303 - 308
12345